US Bancorp DE Sells 1,382 Shares of Omnicell, Inc. (NASDAQ:OMCL)

US Bancorp DE reduced its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 39.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,116 shares of the company’s stock after selling 1,382 shares during the period. US Bancorp DE’s holdings in Omnicell were worth $94,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Van ECK Associates Corp boosted its holdings in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after purchasing an additional 315 shares during the period. First Horizon Advisors Inc. boosted its holdings in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after purchasing an additional 355 shares during the period. KBC Group NV boosted its holdings in shares of Omnicell by 60.8% during the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after purchasing an additional 778 shares during the period. CIBC Asset Management Inc purchased a new stake in shares of Omnicell during the fourth quarter worth about $201,000. Finally, Apollon Wealth Management LLC purchased a new stake in shares of Omnicell during the third quarter worth about $249,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on OMCL shares. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a report on Thursday, March 6th. JPMorgan Chase & Co. raised their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Bank of America lowered their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Benchmark restated a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. Finally, Wells Fargo & Company lowered their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Omnicell presently has a consensus rating of “Hold” and an average target price of $52.33.

Omnicell Price Performance

OMCL stock opened at $33.00 on Monday. The firm has a 50 day moving average price of $40.71 and a 200-day moving average price of $43.27. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.75. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of 122.23, a PEG ratio of 7.53 and a beta of 0.85. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Equities research analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.